Antibody Response 3 Months after 2-Dose SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease

Evangelos Tsipotis, Sarah Frey, Caoilfhionn Connolly, William A. Werbel, Reezwana Chowdhury, Sharon Dudley-Brown, Joanna M. Melia, Alyssa M. Parian, Brindusa Truta, Huimin Yu, Florin M. Selaru, Dorry L. Segev, Mark Lazarev

Research output: Contribution to journalArticlepeer-review

Abstract

INTRODUCTION:The response to SARS-CoV-2 vaccination of patients with inflammatory bowel disease (IBD) on immune-modifying therapies requires further investigation because previous studies indicate that patients on immune therapy might have decreased antibody concentrations.METHODS:We present the antireceptor binding domain antibody response over a period of 3 months in 217 patients with IBD who completed standard 2-dose SARS-CoV-2 mRNA vaccine series.RESULTS:Almost all (98.6%) IBD vaccine recipients had a positive antireceptor binding domain antibody response at least 3 months after vaccination. Decreased antibody titers at 3 months were seen in a subset of patients on antitumor necrosis factor-alpha. Approximately 10% of the participants with high-titer antibodies at 1 month had a decrease to low-positive titers at 3 months, which was mostly observed in those on combination therapy and antitumor necrosis factor-alpha monotherapy.DISCUSSION:Larger longitudinal studies are required to define the response in IBD population and its clinical impact.

Original languageEnglish (US)
Pages (from-to)798-801
Number of pages4
JournalAmerican Journal of Gastroenterology
Volume117
Issue number5
DOIs
StatePublished - May 1 2022

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint

Dive into the research topics of 'Antibody Response 3 Months after 2-Dose SARS-CoV-2 mRNA Vaccination in Patients with Inflammatory Bowel Disease'. Together they form a unique fingerprint.

Cite this